Technological advances make it increasingly easier to predict the risk of Alzheimer's dementia years before the first symptoms appear—currently in people with mild cognitive impairment. In the future, it should become possible to determine the individual risk of developing the disease for people without cognitive impairment using simple blood tests based on disease-specific biomarkers. What does it mean for those affected, their families, and our healthcare system when it becomes increasingly possible and commonplace to know one's specific risk of developing Alzheimer's dementia?

At the international final symposium of this European research project, researchers from various disciplines will present their findings and an ethical framework for better risk assessment for Alzheimer's dementia in clinical practice. Accompanied by commentary from leading experts, we will discuss the findings together.